Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · see citing works

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works

Candidate gene for the chromosome 1 familial Alzheimer’s disease locus

Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · see citing works

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · see citing works

Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values

Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 863 · see citing works

Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein

Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 827 · see citing works

Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values

Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517709091496 · Cited by 813 · see citing works

Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.

Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

Amyloid precursor protein processing and Aβ 42 deposition in a transgenic mouse model of Alzheimer disease

Johnson‐Wood, K., Lee, M., Motter, R. N., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M. N., Tan, H. T., Games, D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1550 · Cited by 634 · see citing works

Aqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion

Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., & Bush, A. I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23223 · Cited by 482 · see citing works

Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay

Ida, N., Hartmann, T., Pantel, J., Schrüder, J., Zerfaß, R., Fürstl, H., Sandbrink, R., Masters, C. L., & Beyreuther, K. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22908 · Cited by 476 · see citing works

Report of the second dementia with Lewy body international workshop

McKeith, I. G., Perry, E. K., & Perry, R. H. (1999) · Neurology · doi:10.1212/wnl.53.5.902 · Cited by 464 · see citing works

High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype

Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442 · see citing works

Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths

Snyder, S. W., Ladror, U. S., Wade, W. S., Wang, G. T., Barrett, L. W., Matayoshi, E. D., Huffaker, H. J., Krafft, G. A., & Holzman, T. F. (1994) · Biophysical Journal · doi:10.1016/s0006-3495(94)80591-0 · Cited by 381 · see citing works

Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340 · see citing works

Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma

Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · see citing works

Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy

Pitschke, M., Prior, R., Haupt, M., & Riesner, D. (1998) · Nature Medicine · doi:10.1038/nm0798-832 · Cited by 326 · see citing works

Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood

Chen, M., Inestrosa, N. C., Ross, G. S., & Fernandez, H. L. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2103 · Cited by 320 · see citing works

Guidelines for immunoassay data processing.

Dudley, R. A., Edwards, P., Ekins, R. P., et al. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.8.1264 · Cited by 288 · see citing works

Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Andreasen, N. C., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B. G., & Blennow, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00617-5 · Cited by 236 · see citing works

Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma

Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2222 · Cited by 230 · see citing works

Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries

Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample

Andreasen, N. C., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B. G., & Blennow, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1488 · Cited by 210 · see citing works

Amyloid β‐Protein Induces Its Own Production in Cultured Degenerating Cerebrovascular Smooth Muscle Cells

Davis-Salinas, J., Saporito-Irwin, S. M., Cotman, C. W., & Nostrand, W. E. V. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020931.x · Cited by 166 · see citing works

Endogenous Proteins Controlling Amyloid β-Peptide Polymerization

Bohrmann, B., Tjernberg, L. O., Kuner, P., Poli, S. M., Levet‐Trafit, B., Näslund, J., Richards, G. J., Huber, W., Döbeli, H., & Nordstedt, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.15990 · Cited by 157 · see citing works

Amyloid β protein in plasma from patients with sporadic Alzheimer's disease

Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 154 · see citing works

The Soluble Form of Alzheimer′s Amyloid β Protein Is Complexed to High Density Lipoprotein 3 and Very High Density Lipoprotein in Normal Human Plasma

Koudinov, A. R., Matsubara, E., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2788 · Cited by 141 · see citing works

Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy

Mackic, J. B., Weiss, M., Miao, W., Kirkman, E., Ghiso, J., Calero, M., Bading, J., Frangione, B., & Zlokovic, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010210.x · Cited by 140 · see citing works

Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., & Mori, H. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00314-0 · Cited by 139 · see citing works

Soluble Amyloid β-Protein Is a Marker of Alzheimer Amyloid in Brain But Not in Cerebrospinal Fluid

Tabaton, M., Nunzi, M. G., Xue, R., Usiak, M., AUTILIO‐GAMBETTI, L., & Gambetti, P. L. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1634 · Cited by 126 · see citing works

Increased plasma amyloid β protein 1–42 levels in Down syndrome

Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108 · see citing works

The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43)

Kosaka, T., Imagawa, M., Seki, K., Arai, H., Sasaki, H., Tsuji, S., Asami-Odaka, A., Fukushima, T., Imai, K., & Iwatsubo, T. (1997) · Neurology · doi:10.1212/wnl.48.3.741 · Cited by 106 · see citing works

Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome

Tokuda, T., Fukushima, T., Ikeda, S., Sekijima, Y., Shoji, S., Yanagisawa, N., & Tamaoka, A. (1997) · Annals of Neurology · doi:10.1002/ana.410410220 · Cited by 92 · see citing works

Alzheimer's soluble amyloid β is a normal component of human urine

Ghiso, J. A., Calero, M., Matsubara, E., Governale, S., Chuba, J. V., Beavis, R. C., Wısnıewskı, T., & Frangione, B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00400-6 · Cited by 90 · see citing works

Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease

Southwick, P. C., Yamagata, S. K., Echols, C. L., Higson, G. J., Neynaber, S. A., Parson, R. E., & Munroe, W. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010259.x · Cited by 89 · see citing works

Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls

Pirttilä, T., Kim, K. S., Mehta, P. D., Frey, H., & Wı́sniewski, H. M. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90140-6 · Cited by 79 · see citing works

Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N. C., Seubert, P. A., VOORDE, A. V. D., & Vanmechelen, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_110 · Cited by 70 · see citing works

Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging

Schröder, J., Pantel, J., Ida, N., Essig, M., Hartmann, T., Knopp, M. V., Schad, L. R., Sandbrink, R., Sauer, H., Masters, C. L., et al. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000313 · Cited by 55 · see citing works

Evidence That Aβ42 Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype

Jonghe, C. D., Cras, P. P., Vanderstichele, H., Cruts, M., Vanderhoeven, I., Smouts, I., Vanmechelen, E., Martin, J.-J., Hendriks, L., & Broeckhoven, C. V. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0247 · Cited by 45 · see citing works

The effects of aspartic acid‐bond isomerization on in vitro properties of the amyloid β‐peptide as modeled with N‐terminal decapeptide fragments

Szendrei, G. I., Prammer, K. V., VASKO, M., LEE, V. M. ‐., & Ötvös, L. (1996) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1996.tb01358.x · Cited by 27 · see citing works

Quantitative Models for Prediction of Toxic Component Concentrations in Smoke Gases from FTIR Spectra

Pottel, H. (1996) · Fire and Materials · doi:10.1002/(sici)1099-1018(199611)20:6 · Cited by 18 · see citing works

Untitled work

Kordower (1999) · doi:10.1002/1531-8249(199909)46:3

Untitled work

(1999) · doi:10.1002/1531-8249(199904)45:4

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · see citing works

Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk

Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434 · see citing works

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358 · see citing works

Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247 · see citing works

Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible

Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182 · see citing works

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls

Martínez-Morillo, E., Hansson, O., Atagi, Y., Bu, G., Minthon, L., Diamandis, E. P., & Nielsen, H. M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1266-2 · Cited by 168 · see citing works

Circulating Biomarkers of Cognitive Decline and Dementia

Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120 · see citing works

Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119 · see citing works

Increased Protein and Lipid Oxidative Damage in Mitochondria Isolated from Lymphocytes from Patients with Alzheimer's Disease: Insights into the Role of Oxidative Stress in Alzheimer's Disease and Initial Investigations into a Potential Biomarker for this Dementing Disorder

Sultana, R., Mecocci, P., Mangialasche, F., Cecchetti, R., Baglioni, M., & Butterfield, D. A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101425 · Cited by 111 · see citing works

Association of cerebrospinal fluid α‐synuclein with total and phospho‐tau₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers

Vergallo, A., Bun, R., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Cavedo, E., Lamari, F., Habert, M., Dubois, B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3053 · Cited by 59 · see citing works

Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease

Ewers, M., Cheng, X., Zhong, Z., Nural, H. F., Walsh, C., Meindl, T., Teipel, S. J., Buerger, K., He, P., Shen, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-091153 · Cited by 58 · see citing works

Two‐level diagnostic classification using cerebrospinal fluid YKL‐40 in Alzheimer's disease

Baldacci, F., Toschi, N., Lista, S., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S., Cavedo, E., dos Santos, A. M., Epelbaum, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.021 · Cited by 53 · see citing works

The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: Correlation with cognitive and functional decline

Öztürk, C., Özge, A., Yalın, O. Ö., Yılmaz, &. A., Delialioglu, N., Yıldız, Ç., Tesdelen, B., & Kudiaki, C. (2007) · Behavioural Neurology · doi:10.1155/2007/432190 · Cited by 46 · see citing works

Progress and challenges in the diagnosis of dementia: a critical review

Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31 · see citing works

Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment

Johansson, P., Almqvist, E. G., Wallin, A., Johansson, J.-O., Andreasson, U., Blennow, K., Zetterberg, H., & Svensson, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176760 · Cited by 20 · see citing works

Lipoprotein(a) in the Cerebrospinal Fluid of Neurological Patients with Blood–Cerebrospinal Fluid Barrier Dysfunction

Pepe, G., Chimienti, G., Liuzzi, G. M., et al. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.073544 · Cited by 14 · see citing works

“Compensated hyperosmolarity” of cerebrospinal fluid and the development of hydrocephalus

Klarica, M., Miše, B., Vladić, A., Radoš, M., & Orešković, D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.022 · Cited by 55 · see citing works

Cerebrospinal Fluid Thyroxine

Hansen, J., & Siersbæk‐Nielsen, K. (1969) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-29-8-1023 · Cited by 9 · see citing works

Transient Elevation of Granulocyte Colony-Stimulating Factor Levels in Cerebrospinal Fluid at the Initial Stage of Aseptic Meningitis in Children

Fukushima, K., Ishiguro, A., & Shimbo, T. (1995) · Pediatric Research · doi:10.1203/00006450-199502000-00006 · Cited by 23 · see citing works

Cerebrospinal Fluid Production by the Choroid Plexus and Brain

Milhorat, T. H., Hammock, M. K., Fenstermacher, J. D., et al. (1971) · Science · doi:10.1126/science.173.3994.330 · Cited by 222 · see citing works